Precision medicine in asthma: linking phenotypes to targeted treatments
|
|
- Gervais Grant
- 6 years ago
- Views:
Transcription
1 REVIEW C URRENT OPINION Precision medicine in asthma: linking phenotypes to targeted treatments Kian F. Chung a,b Purpose of review Asthma is a heterogeneous disease consisting of different phenotypes that are driven by different mechanistic pathways. The purpose of this review is to emphasize the important role of precision medicine in asthma management. Recent findings Despite asthma heterogeneity, the approach to management has been on the basis of disease severity, with the most severe patients reserved for the maximum treatments with corticosteroids and bronchodilators. At the severe end, the recent availability of biologic therapies in the form of anti-ige (omalizumab) and anti- IL5 therapies (mepolizumab and reslizumab) has driven the adaptation of precision medicine. These therapies are reserved for severe asthma with defined either allergic or eosinophilic background, respectively. Summary Unbiased definition of phenotypes or endotypes (which are phenotypes defined by mechanisms) is an important step towards the use of precision medicine in asthma. Although T2-high asthma has been defined with targets becoming available for treating allergic or eosinophilic asthma, the definition of non-t2 phenotypes remains a priority. Precision medicine is also dependent on the definition of biomarkers that can help differentiate between these phenotypes and pinpoint patients suitable for specific-targeted therapies. Thus, precision medicine links phenotypes (endotypes) to targeted treatments for better outcomes. Keywords asthma, biomarkers, phenotyping, precision medicine INTRODUCTION Asthma is diagnosed by the presence of intermittent symptoms of wheeze, cough and chest tightness that usually resolves spontaneously or with asthma treatments, and under such an umbrella term, would exist different phenotypes of asthma. In fact, the Global Initiative for Asthma (GINA) has now recognized asthma as being a heterogeneous disease with different presentations, outcomes and underlying mechanisms. Clinicians have defined several phenotypes based on the presentation and age of onset of symptoms, the severity of the disease and the presence of other conditions such as allergy and eosinophilia. When these phenotypes have been linked to long-term outcomes or to response to therapy with corticosteroids, these have been used by clinicians to predict the course of asthma. Despite the recognition of these phenotypes of asthma, the approach to the management of asthma continues to be based on the severity of the condition, with drugs added on the basis of asthma control. Inhaled corticosteroid (ICS) therapy remains the cornerstone of treatment of asthma because asthma is recognized as an eosinophilic inflammatory condition; however, those who respond to ICS therapy with an improvement in lung function such as the forced expiratory volume measured in one second (FEV 1 ) are associated with eosinophilia, and these usually represent up 50% of asthmatic patients [1,2]. The use of blood eosinophil count as a biomarker to define responders to ICS is not used. Treatment of patients with asthma based on their sputum eosinophil counts rather than on symptoms results in better control of asthma with less exacerbations using less corticosteroid therapy [3]. There may be many reasons why this approach of using sputum a National Heart and Lung Institute, Imperial College London and b Res- Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, Imperial College London, London, UK Correspondence to Professor Kian F. Chung, MD, DSc, FRCP, National Heart and Lung Institute, Imperial College London, Dovehouse St, London SW3 6LY, UK. Tel: ; f.chung@imperial.ac.uk Curr Opin Pulm Med 2017, 23: DOI: /MCP Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved.
2 Asthma KEY POINTS Severe asthma is a heterogeneous condition and phenotyping of patients with severe asthma into a T2 and non-t2 category is possible. Precision medicine is being introduced with the availability of biologic therapies targeting IgE and IL-5, because these agents are targeted towards specific phenotypes of severe asthma. The future of precision medicine in asthma will depend on the unbiased recognition of all the molecular phenotypes or endotypes of asthma, and the definition of associated biomarkers. eosinophil counts to improve the therapy of asthma has not been adopted. Most importantly, obtaining sputum samples from patients with asthma is not always successful and the analysis of the samples takes time and effort. Thus, the practice of precision (or personalized) medicine in asthma is lagging behind. However, the introduction of specific biologic therapies such as anti-ige and anti-il5 antibody treatments at the step 5 of the GINA guidelines has opened up the new era of precision medicine in asthma. These therapies are only used in the severe allergic asthma and in the severe eosinophilic phenotypes of asthma, respectively. Although the practice of medicine has always been based on a personalized approach since the dawn of medicine, with the concept of treating each patient as being unique, this delivery has remained very limited mainly as a concept rather than hard practice because of limitations in our understanding of what constitutes asthma. Currently, we recognize a category of asthma as being severe asthma, defined as by poor therapeutic responses of these patients to currently approved asthma medications, particularly inhaled and oral corticosteroid therapies, and approaches to phenotyping have been proposed in the international severe asthma guidelines [4]. The clinical diversity of this group has been recognized and this group of patients has been the subject of unbiased clustering approaches. Phenotypes of asthma have not been well described and there has been a lack of biomarkers developed for identifying different types of asthma. Consequently, the treatment of asthma has remained a one size fits all. Treatments should not only be based on the basis of severity, but on the basis of the driving mechanisms. The introduction of new biologic therapies at step 5 has heralded a new era of precision medicine for asthma. This review will discuss how precision medicine will alter the approach to the management of asthma. WHAT IS PRECISION MEDICINE? Precision medicine can be defined as an approach to treat and prevent disease by taking into consideration the individual variability in genes, environment and lifestyle for each individual and by taking this approach, there is increased likelihood of treating the right patient with the right drug at the right time, with preventive measures and therapies tailored for each individual [5]. Analysis of the genes and proteins is more likely to point towards causative pathways, which would lead to definition of endotypes which are phenotypes defined according to mechanisms. This is more likely to lead to treatments that target the cause of these diseases. Precision medicine is the tailoring of medical management to the individual characteristics not only genetic or genomic but also environmental and psychosocial characteristics, and preferences of each patient. Other terms that are used often synonymously with precision medicine are tailored medicine, stratified medicine or targeted medicine that will ultimately lead to targeted therapeutics. The concept of the P4 medicine that is predictive, preventive, personalized and participatory also falls within a similar definition ( systemsbiology.org/research/p4-medicine/). In order to be able to practise precision medicine with particular reference to asthma, one should understand the different endotypes of asthma and the biomarkers that will be used to help the doctor in determining the right treatment. In addition, because asthma is a disease that changes with time, information on a daily basis about the patient s condition and environment that could influence the course of the disease is needed. Such daily information may be used to predict any future exacerbations of asthma and the influence of potential environmental factors. PHENOTYPING TO ENDOTYPING Description of clinical phenotypes based on clinical variables and inflammatory markers has been made possible by the use of unbiased methods of clustering. The most recent report from the U-BIOPRED cohort described a well-controlled moderate-tosevere asthma phenotype and three other severe phenotypes: late-onset asthma with past or current smoking and chronic airflow obstruction, predominantly eosinophilic inflammation, nonsmoking severe asthma with chronic airflow obstruction and high use of oral corticosteroid therapy and obese female patients with frequent exacerbations but with normal lung function [6 ] (Fig. 1). In the American Severe Asthma Research Project (SARP) cohort, phenotypes of early-onset atopic asthma 2 Volume 23 Number 00 Month 2017
3 Precision medicine for asthma Chung FIGURE 1. Clinical phenotypes of moderate severe asthma derived from U-BIOPRED cohort from a cluster analysis of eight clinico-physiologic parameters. Reproduced from [6 ] (with permission). with mild-to-moderate severity, of obese late-onset nonatopic asthma female patients with frequent exacerbations and of those with severe airflow obstruction with use of oral corticosteroid therapy were identified [7]. In the Leicester cohorts, the use of sputum eosinophilia as a marker of eosinophilic asthma [8] has resulted in the description of two cohorts: a cluster of noneosinophilic inflammation (early-onset, symptom-predominant group in female obese patients) and a cluster of eosinophilic inflammation with late-onset disease, associated with rhinosinusitis, aspirin sensitivity and recurrent exacerbations. This latter eosinophilic phenotype was also described in the SARP cohort with late-onset asthma and nasal polyps with exacerbations despite high systemic corticosteroid use; the other eosinophilic cohort had early-onset allergic asthma with low lung function [9]. This clustering based on clinical, physiological and inflammatory parameters while yielding distinct phenotypes has not in general led to the elaboration of phenotypic biomarkers. DEFINITION OF A SEVERE EOSINOPHILIC ASTHMA PHENOTYPE/ENDOTYPE Molecular phenotyping has allowed us to define the severe eosinophilic asthma phenotype as an endotype, that is a phenotype defined by underlying mechanisms. The clinical phenotype characterized by concomitant high blood and sputum eosinophilia has been associated with very poor asthma control and propensity to asthma exacerbation [9] Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. 3
4 Asthma The unbiased cluster analyses have uncovered a phenotype of patients with late-onset, eosinophilic inflammation-predominant asthma [6,7,8], and adult-onset asthma patients with a high blood eosinophil count with frequent exacerbations and a poor prognosis [10]. Persistent airflow limitation and distal inflammation with air trapping are common in these patients, as is upper airway disease such as chronic rhinosinusitis with nasal polyposis [11]. Molecular support for this endotype was provided by determining the expression of three genes upregulated by exposing airway epithelial cells to the T2 cytokine, interleukin-13 (IL-13), in airway epithelial cells of patients with asthma. A Th2-high molecular phenotype was characterized by more blood and bronchoalveolar lavage eosinophils, increased levels of serum immunoglobulin E (IgE), increased expression of mucin MUC5AC, increased expression of IL5 and IL13 in biopsies, increased bronchial hyperresponsiveness and respond to ICSs by an increase in FEV 1 when compared to those with Th2-low expression [12]. Finally, the recent sputum analysis of U-BIOPRED has defined the molecular shape of this endotype associated with high T2 pathway and also with mast cell activation pathway [13 ]. New targeted treatments such as anti-il5 and anti-il5ra antibody that caused a reduction in the exacerbation rate support the concept that this is a severe eosinophilic asthma endotype [14,15 ]. The major criteria for this endotype have been defined as having severe asthma, with high load eosinophilic disease, having frequent exacerbations and the need for oral corticosteroid therapy to maintain control [16]. UNBIASED MOLECULAR PHENOTYPING The Th2-high phenotype is only found in 37% of patients with severe asthma when analysing genes in the airway epithelium [17]. Therefore, the majority of patients with severe asthma can be considered to be low-t2. In order to elucidate these non-t2 endotypes, an unbiased approach to obtaining molecular phenotypes of asthma was undertaken in U-BIOPRED. A hierarchical clustering of differentially expressed genes between eosinophilic and noneosinophilic inflammatory profiles from an analysis of sputum omics data revealed three molecular phenotypes [13 ]. One cluster was characterized by the immune receptors IL33R, CCR3 and TSLPR with the highest enrichment of gene signatures for IL- 13/T-helper cell type 2 (Th2) and innate lymphoid cell type 2 associated with the highest sputum eosinophilia: this grouped patients with severe asthma with oral corticosteroid dependency, frequent exacerbations and severe airflow obstruction. The second cluster was characterized by interferon-a (IFN-a), tumour necrosis factor-a-associated (TNF-a) and inflammasome-associated genes with the highest sputum neutrophilia, serum C-reactive protein levels and prevalence of eczema. The third phenotype was characterized by genes of metabolic pathways, ubiquitination and mitochondrial function with paucigranulocytic inflammation and little airflow obstruction [13 ]. The second phenotype is in agreement with the report that in neutrophilic asthma, an elevated gene expression of NLRP3, caspase-1 and IL- 1b was seen in sputum macrophages [18]. Thus, this unbiased approach has provided an overall idea of the various pathways associated with these three phenotypes of asthma, with the possibility that each of these phenotypes is underlined by several interacting pathways. Therefore, within this categorization, it has been possible to define an eosinophilic inflammation phenotype, a neutrophilic phenotype and a paucigranulocytic phenotype according to sputum cell measurements. Furthermore, each inflammatory phenotype was observed with several pathways that could contribute to the definition of the phenotype. However, because there has been no validation of these pathways yet, it is not possible to describe these as endotypes yet. One could consider the cluster associated with the highest expression of T2 and ILC2 pathway signature and sputum eosinophilia to be a severe eosinophilic asthma endotype. On the contrary, the neutrophilic cluster associated with inflammasome activation cannot be considered an endotype yet, because the role of the inflammasome in this cluster is yet to be defined. Nevertheless, this remains a potential therapeutic target for this cluster. Similarly, this similar argument can be made for the third cluster that may be driven by mitochondrial oxidative stress pathways. DEVELOPMENT OF TARGETED THERAPIES Recent progress in the therapy of severe asthma has been marked by the introduction of biologic treatments as add-on treatment to step 5 of the GINA guidelines. Such biologic treatments have now been important in defining the target population, not only because these treatments are relatively expensive compared to existing ones but also because such specific targeting needs to be used only in those who have the target abnormality. However, cost-effectiveness analyses will be needed to determine the true costs of these treatments. These biologic treatments being very specific in their actions in targeting single cytokines have opened up the field of precision medicine, placing the emphasis on the application of precision medicine in severe asthma 4 Volume 23 Number 00 Month 2017
5 Precision medicine for asthma Chung as the correct patient needs to be singled out for these specifically targeted treatments. The greatest emphasis has been on the targeted treatments for the T2 pathway, whereas treatments targeted at non-t2 pathways have been less successful [19 & ]. associated with lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts in patients with uncontrolled moderateto-severe asthma [27]. TARGETING THE T2 PATHWAY Activation of Th2 and ILC2 cells can occur through the release of innate cytokines, such as thymic stromal lymphopoietin (TSLP), IL-25 and IL-33 from the epithelium, which can be induced by external stimuli such as lipopolysaccharide, pollutants and viruses [20]. These activated Th2 or ILC2 cells release IL4, 5 and 13, which are expressed in the bronchial submucosa of patients with asthma. The new biologic treatments available for patients with severe asthma include anti-ige antibody and anti-il5 antibody. Anti-IgE antibody prevents the binding of free IgE to IgE receptors on mast cells and basophils by binding itself to free IgE. IgE production from B cells is under the control of the T2 cytokines, IL-4 and IL- 13. Anti-IL5 antibody is targeted towards IL-5, produced by Th2 cells and ILC2s and is important for the terminal differentiation and maturation of eosinophils in the bone marrow and for the mobilization of eosinophils and eosinophil precursors into the circulation. Both anti-ige antibody and anti-il5 antibody are targeted for use in patients with severe asthma, the former for allergic asthmatic patients and the latter for eosinophilic asthma. In severe persistent allergic asthma defined by patients with an allergic background with raised serum IgE levels and at step 4 or 5 of GINA guidelines, omalizumab, an anti-ige antibody, as an add-on therapy decreased severe asthma exacerbations by 26%, compared with placebo [21]. Mepolizumab and reslizumab, anti-il5 antibodies, have been shown to benefit allergic and eosinophilic severe asthma, respectively, by reducing asthma exacerbation frequency and also improving baseline airflow obstruction [22,23 ]: the patients chosen for these studies had to show a raised level of blood eosinophil count. Other potential therapies not yet approved targeting T-2 pathway include anti-il5ra antibody (benralizumab) that inhibits the effect of IL5 [24,25 ], and anti-il4ra antibody (dupilumab) [26 ] that blocks the effects of IL-13 and IL-4 together, both showing beneficial effects on exacerbations and lung function, particularly in those with a raised blood eosinophil count. More recently, tezepelumab (AMG 157/ MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine TSLP which regulates type 2 immunity through not only Th2 cells but also through ILC2 cells, has been NON-T2 TARGETS There have been descriptions of non-t2 phenotypes previously. Thus, a systemic IL-6 inflammation with clinical features of metabolic dysfunction associated with more severe asthma has been described [28]. In addition, apart from Th2 high, a Th17 high group has been described with the Th2 high being mutually exclusive of Th17 high [29]. However, despite this targeting non-t2 targets, it has not proven to be successful in providing effective therapies for asthma. Brodalumab, a human anti-il-17ra monoclonal antibody, had no effect on asthma control scores, symptom-free days and FEV 1 in patients with inadequately controlled moderate-to-severe asthma who were receiving ICS therapy [30]. Treatment with a selective CXCR2 antagonist, AZD5069, which blocks the effect of CXCL8, did not reduce the frequency of severe exacerbations in patients with uncontrolled severe asthma [31]. Finally, in adults with uncontrolled severe persistent asthma, the anti-tnfa antibody golimumab had no overall beneficial effects [32]. These have raised the issue as to whether a neutrophilic asthma phenotype does exist [33], but it is more likely that the reason for the failure of these therapies is that the right patients were not chosen for these therapies with the lack of the appropriate biomarkers. The molecular phenotypes derived from sputum transcriptomic analysis in U-BIOPRED defined a neutrophilic inflammatory phenotype (sputum neutrophil >73%), with inflammasome, IFN and TNF activation pathways [13 ]. This could be associated with the microbial dysbiosis that is now increasingly being associated with severe asthma [34], but further validation research is needed to definitely determine the mechanism underlying the neutrophilic inflammation. Analysis of transcriptomics in bronchial biopsies and brushings identified the coexpression of high Th2 and high Th1 pathways indicating that more than one pathway may coexist [35 ]. A raised concentration of the gastrotransmitter, hydrogen sulphide, in sputum has also been associated as a potential biomarker of neutrophilic asthma associated with airflow obstruction [36]. BIOMARKERS FOR PRECISION MEDICINE In order to define the phenotypes that constitute the whole range of asthma and to find the patients who Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. 5
6 Asthma will respond to specific therapies, it is important to define the biomarkers that will help the clinician to select the right therapy for the right patient. A biomarker can be defined as a characteristic that can be measured and evaluated as an indicator of normal or pathological biological processes or the biological response to a therapeutic intervention [37]. Biomarkers mostly indicative of T2-high asthma that are easily accessible to the patient are available for the management of asthma; these include blood eosinophil count and serum IgE and also serum periostin levels, levels of nitric oxide in exhaled breath (FeNO) and sputum eosinophil count in some centres. Using sputum eosinophil counts as a response biomarker to treatment with corticosteroid therapy results in better outcome measures mainly in terms of a reduction in exacerbations compared to using symptom severity [38]. FeNO did not perform as well. Responsiveness to corticosteroid therapy particularly in children can be predicted from a blood eosinophil count [39], but validated cut-off levels in different populations still need to be established. Increasingly, biomarkers will be used to select patients who would be suitable for specific biological treatments. Baseline blood eosinophil count is being used as a biomarker that predicts the clinical efficacy of anti-il5 therapy in patients with severe eosinophilic asthma with a history of exacerbations [15,22,40,41]. Total serum IgE level has been used as a response biomarker for the use of anti-ige antibody, omalizumab, in the treatment of severe allergic asthma. High levels of FeNO (>19.5 parts per billion) and blood eosinophil count (>260/ml) significantly predicted those responding to omalizumab with a reduction in exacerbations [42]. There is an increasing need for developing biomarkers that will guide clinicians in the management of asthma. The following areas need further development: definition of molecular phenotypes of asthma, particularly those in the non-t2/th2 pathways, develop more phenotypic and predictive biomarkers to delineate these molecular phenotypes of asthma and obtain specific biomarkers to predict therapeutic outcomes to more specific targeted therapies. An unbiased approach is necessary to define the phenotypes of asthma. Although the use of omics data from multiple platforms including transcriptomics, proteomics, lipidomics or metabolomics in lung tissue compartments holds the best chance of obtaining endotypes [43,44], biomarkers need to be developed in easily accessible compartments, so-called bedside biomarkers, which can be assayed relatively easily. Thus, assays involving exhaled breath, blood or urine would appear more promising. Therefore, one unmet need is how to develop such bedside biomarkers. The other possibility is that composite biomarkers may be another answer to this [45]. CONCLUSION Because of the heterogeneity and complexity of asthma, a different approach from current practice is needed to the management of asthma that takes into account these varied features of the disease. The use of omics data and unbiased clustering together with the use of clinical features, physiological and inflammatory data will provide greater opportunity of phenotyping asthma according to the mechanisms driving the disease thus leading to endotype definition. Biomarkers could be used to define and categorize these endotypes. This will be a tremendous help for the development of precision medicine for asthma that will allow for more precise treatment aims and also provide a source of novel targets and hence new treatments for each defined endotype. Precision medicine should be applied to the whole spectrum of asthma, not just at the more severe end of the disease. Acknowledgements K.F.C. is a Senior Fellow of the National Institute for Health Research, UK. He also acknowledges support from the Medical Research Council and European Union. Financial support and sponsorship K.F.C. reports personal fees from Advisory Board membership with GSK, Boehringer Ingelheim, Novartis, Astra-Zeneca and Teva, personal fees from payments for lectures from Astra-Zeneca, Novartis and Merck, and grants for research to his institution from Merck and GSK, all in relation to asthma, COPD and cough. Conflicts of interest There are no conflicts of interest. REFERENCES AND RECOMMENDED READING Papers of particular interest, published within the annual period of review, have been highlighted as: & of special interest of outstanding interest 1. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: Volume 23 Number 00 Month 2017
7 Precision medicine for asthma Chung 5. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013; 1: Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum -omics. J Allergy Clin Immunol 2016; 139: Unbiased approach to defining clinical phenotypes of severe asthma. 7. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 2014; 133: Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3: de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adultonset eosinophilic asthma. ERJ Open Res 2016; 2: pii: Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: Kuo CS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-th2 molecular phenotypes of asthma using sputum transcriptomics in U- BIOPRED. Eur Respir J 2017; 49: pii: Unsupervised molecular phenotyping of severe asthma using sputum transcriptomics to define three molecular phenotypes, of which two are non-t2 phenotypes. 14. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5: Phase 3 trial of an anti-il5 antibody for severe eosinophilic asthma. 15. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: Phase 3 trial of an anti-il-5 receptor antibody for severe eosinophilic asthma. 16. Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017; 49: pii: Pavlidis S, Loza M, Baribaud F, et al. Th2 subsetting of U-BIOPRED asthma subjects based on airway transciptomic profiles. Eur Respir J 2015; 46(Suppl 59):OA Simpson JL, Phipps S, Baines KJ, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 2014; 43: & Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386: Summarizes the new biologic targets for treating severe asthma. 20. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013; 14: Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: Phase 3 trial of an anti-il5 antibody in severe eosinophilic asthma. 24. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: Phase 3 trial of an anti-il5 receptor antibody in severe eosinophilic asthma. 25. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an antiinterleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2016; 388: Phase 3 trial of an anti-il5 antibody in severe eosinophilic asthma. 26. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388: Phase 2 trial of an anti-il4 receptor antibody in severe eosinophilic asthma. 27. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017; 377: Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 2016; 4: Choy DF, Hart KM, Borthwick LA, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7:301ra Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebocontrolled study of brodalumab, a human anti-il-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: O Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4: Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: Chung KF. Neutrophilic asthma: a distinct target for treatment? Lancet Respir Med 2016; 4: Chung KF. Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment? J Allergy Clin Immunol 2017; 139: Kuo CS, Pavlidis S, Loza M, et al. A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U- BIOPRED. Am J Respir Crit Care Med 2017; 195: A semisupervised molecular clustering of the bronchial brushing and biopsy transcriptome characterizing a Th2-high molecular phenotype. 36. Saito J, Zhang Q, Hui C, et al. Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma. J Allergy Clin Immunol 2013; 131: Amur S, LaVange L, Zineh I, et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther 2015; 98: Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and metaanalysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: Gaillard EA, McNamara PS, Murray CS, et al. Blood eosinophils as a marker of likely corticosteroid response in children with preschool wheeze: time for an eosinophil guided clinical trial? Clin Exp Allergy 2015; 45: Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: Chung KF, Adcock IM. Clinical phenotypes of asthma should link up with disease mechanisms. Curr Opin Allergy Clin Immunol 2015; 15: Heaney LG, Djukanovic R, Woodcock A, et al. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax 2015; 71: Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. 7
Personalised medicine in asthma: time for action
SERIES PERSONALISED MEDICINE Personalised medicine in asthma: time for action Kian Fan Chung 1,2 Number 1 in the Series Personalised medicine in respiratory diseases Edited by Renaud Louis and Nicolas
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationPredicting response to triamcinolone in severe asthma by machine learning: solving the Enigma
Page 1 of 5 Predicting response to triamcinolone in severe asthma by machine learning: solving the Enigma Kian Fan Chung National Heart & Lung Institute, Imperial College London & Royal Brompton and Harefield
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationSevere eosinophilic asthma: a roadmap to consensus
EDITORIAL EOSINOPHILIC ASTHMA Severe eosinophilic asthma: a roadmap to consensus Roland Buhl 1, Marc Humbert 2, Leif Bjermer 3, Pascal Chanez 4, Liam G. Heaney 5, Ian Pavord 6, Santiago Quirce 7, Johann
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationSubclinical phenotypes of asthma
1 Subclinical phenotypes of asthma P Bradding DM FRCP*, RH Green MD FRCP* * Institute for Lung Health and Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK Department of Infection,
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More information10/24/2016. Precision Management of Severe Asthma How, When and Where. The Goals of Today s Presentation
1/24/216 Precision Management of Severe Asthma How, When and Where. Reynold A. Panettieri, Jr., MD Vice Chancellor for Clinical & Translational Science Director, Rutgers Institute for Translational and
More informationIoana Agache Transylvania University Brasov. Precision medicine in allergy and asthma
Ioana Agache Transylvania University Brasov Precision medicine in allergy and asthma Precision medicine and precision health Personalized care based on molecular, immunologic and functional endotyping
More informationBiomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus
ORIGINAL RESEARCH LETTER Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus To the Editor: Asthma is managed using step-wise adjustment of corticosteroid therapy to
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More informationSingle Technology Appraisal (STA) Benralizumab for treating severe asthma
Single Technology Appraisal (STA) Benralizumab for treating severe asthma Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments received
More informationPotential new targets for drug development in severe asthma
Zhu et al. World Allergy Organization Journal (2018) 11:30 https://doi.org/10.1186/s40413-018-0208-1 REVIEW Potential new targets for drug development in severe asthma Linda Zhu 1,2, Christina E. Ciaccio
More informationManaging severe asthma in adults: lessons from the ERS/ATS guidelines
REVIEW C URRENT OPINION Managing severe asthma in adults: lessons from the ERS/ATS guidelines Kian Fan Chung a,b Purpose of review To review the latest guidelines on severe asthma. Recent findings An updated
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationSEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA
SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA FIND OUT MORE VISIT - WWW.NUCALA.CO.UK Vial not actual size
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationBiologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
More informationImproving the diagnosis of eosinophilic asthma
Expert Review of Respiratory Medicine ISSN: 1747-6348 (Print) 1747-6356 (Online) Journal homepage: http://www.tandfonline.com/loi/ierx20 Improving the diagnosis of eosinophilic asthma Hanneke Coumou &
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationJamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
More informationStudy Investigators/Centers: GSK sponsored studies MEA112997, MEA115588, and MEA and a proof of concept investigator sponsored study CRT110184
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSEVERE ASTHMA: not for distribution CHARACTERIZATION FOR INDIVIDUALIZED THERAPY RESPIROLOGY
RESPIROLOGY SEVERE ASTHMA: CHARACTERIZATION FOR INDIVIDUALIZED THERAPY Severe Asthma Phenotypes Richard Leigh, MD, PhD Professor of Medicine University of Calgary Calgary, Alberta Severe Asthma Endotypes
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationAssessment of a rapid liquid based cytology method for measuring sputum cell counts
Assessment of a rapid liquid based cytology method for measuring sputum cell counts Martin MJ, Lee H, Meakin G, Green A, Simms RL, Reynolds C, Winters S*, Shaw DE, Soomro I*, Harrison TW The Asthma Centre
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationSteps to better understand severe asthma in adults
PRESCRIBING IN PRACTICE n Steps to better understand severe asthma in adults Alexandra M Nanzer MRCP and Andrew Menzies-Gow PhD, MB BS Primary care plays an essential role in identifying and supporting
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationReview. Key words : asthma, benralizumab, interleukin-5, mepolizumab, reslizumab. Introduction
Showa Univ J Med Sci 30 1, 11 25, March 2018 Review Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma : A Systematic Review and
More informationUncontrolled Moderate-to-Severe-Asthma: Latest Data from the Floor of CHEST 2018
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationasthma, order-made medicine, phenotypes 2.1 Cluster analysis by Haldar et al.
Received: 8 June 2015 Accepted: 25 February 2016 DOI: 10.1002/jgf2.7 REVIEW ARTICLE Asthma phenotypes Masahiro Hirose MD, PhD Takahiko Horiguchi MD, PhD Department of Respiratory Medicine II, Fujita Health
More informationPrecision Asthma Therapy: Picking the Right Biologic for the Right Patient. The Asthma Umbrella. Asthma. Late onset. Early onset.
recision Asthma Therapy: icking the Right Biologic for the Right atient The Asthma Umbrella Asthma arly onset Late onset Symptoms xacerbations FV1 T H 2 inflammation No or less T H 2 inflammation henotype
More informationBiologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks
Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope June 13, 2018 Background The Centers for
More informationDistinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
More informationImmunotherapy in Asthma Management
SMGr up Immunotherapy in Asthma Management Kurt Munzer 1, Zafar Jamkhana 1 and Setu Patolia 1 * 1 Division of Pulmonary, Critical Care and Sleep Medicine, Saint Louis University, USA *Corresponding author:
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationERJ Express. Published on December 12, 2013 as doi: /
ERJ Express. Published on December 12, 2013 as doi: 10.1183/09031936.00191113 Editorial ERJ: ERS/ATS Guidelines on Severe Asthma Trustworthy Guidelines on Severe Asthma thanks to ERS and ATS Guy G. Brusselle
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationE-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com
More informationAre emerging PGD2 antagonists a promising therapy class for treating asthma?
Expert Opinion on Emerging Drugs ISSN: 1472-8214 (Print) 1744-7623 (Online) Journal homepage: http://www.tandfonline.com/loi/iemd20 Are emerging PGD2 antagonists a promising therapy class for treating
More informationIndirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma Bayesian Analysis of Randomized Controlled Trials
Showa Univ J Med Sci 30 2, 189 196, June 2018 Original Indirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma Bayesian Analysis of Randomized Controlled Trials
More informationRising Incidence of Asthma
Controlling Severe Asthma through Advanced Diagnosis and Treatment Strategies James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at
More informationSevere Asthma Reference Guide Phenotypes, Endotypes, Biomarkers, and Treatment
Severe Asthma Reference Guide Phenotypes, Endotypes, Biomarkers, and Treatment A C M E / C E - c e r t i f i e d s u p p l e m e n t t o C H E S T P hys i c i a n Severe Asthma Reference Guide Phenotypes,
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationRecent changes in the drug treatment of allergic asthma
DRUG THERAPIES IN Clinical Medicine 2013, Vol 13, No 5: 477 81 Recent changes in the drug treatment of allergic asthma David Gibeon and Andrew Menzies-Gow ABSTRACT Asthma is a heterogeneous condition with
More informationRapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
Adv Ther (218) 35:59 68 https://doi.org/.7/s12325-18-727-8 ORIGINAL RESEARCH Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab Hector
More informationNovel Biologics for Asthma: Steps on the Long Road to Therapies for Uncontrolled Asthma
vel Biologics for Asthma: Steps on the Long Road to Therapies for Uncontrolled Asthma LAURA RUNKEL, PHD Associate Director, CNS, Autoimmune/Inflammation Introduction Asthma is one of the most prevalent
More informationAddressing Unmet Medical Needs in Severe Asthma: Where Do We Stand?
Addressing Unmet Medical Needs in Severe Asthma: Where Do We Stand? An Expert Consensus Presented by: Michael Blaiss, MD, FACAAI Mario Castro, MD, MPH Provided by the American College of Allergy, Asthma
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationTargeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review
Targeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review Christine Lam, PharmD, BCPS; Kunal J. Shah, PharmD; and Rupal Mansukhani, PharmD INTRODUCTION Asthma is a chronic
More informationPatients with severe asthma make up only 3%1 to 10%2 of the population
The new england journal of medicine Review Article Jeffrey M. Drazen, M.D., Editor Severe and Difficult-to-Treat Asthma in Adults Elliot Israel, M.D., and Helen K. Reddel, M.B., B.S., Ph.D. Patients with
More informationABCs of Immune Modifiers. Relevant Disclosures
ABCs of Immune Modifiers Dennis K. Ledford, MD Ellsworth and Simmons Professor of Allergy/Immunology University of South Florida Morsani College of Medicine Tampa, FL USA Relevant Disclosures Research
More informationAirway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.
REVIEW ARTICLE Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. 2 Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial
More informationTreatment of Severe Asthma: Biologics to Bronchial Thermoplasty. Disclosures
Treatment of Severe Asthma: Biologics to Bronchial Thermoplasty Monica Kraft, M.D. Robert and Irene Flinn Professor of Medicine Chair, Department of Medicine Deputy Director, Asthma and Airway Disease
More informationProperty of Presenter
Have We Missed A Role For Neutrophils In Asthma? In Steroid-Refractory Asthma? Erwin W. Gelfand, MD Chairman, Department of Pediatrics National Jewish Health Professor of Pediatrics and Immunology University
More informationEFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Severity Assessment, Guidelines, and New Therapeutic Options
Educational Objectives EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP President-Elect, American College of Allergy, Asthma & Immunology Medical Director,
More informationLINEE GUIDA DELL ASMA: UP TO DATE
LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,
More informationEmerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More information10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:
for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationUpdate on Biologicals for ABPA and Asthma
Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA Disease of chronic airway
More informationSEVERE ASTHMA - EVIDENCE TABLES APPENDIX 1
Section 2: Biomarkers Biomarkers to predict response to biologic therapies and macrolides Summary of randomized controlled trials Cut-offs Cut-off selection Study Design N Drug Predictive ability to identify
More informationReview Article Efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a meta-analysis
Int J Clin Exp Med 2018;11(3):1483-1489 www.ijcem.com /ISSN:1940-5901/IJCEM0065120 Review Article Efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a meta-analysis Xiaoyan
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More information5/1/18. Emerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationTezepelumab in Adults with Uncontrolled Asthma
The new england journal of medicine Original Article in Adults with Uncontrolled Asthma Jonathan Corren, M.D., Jane R. Parnes, M.D., Liangwei Wang, Ph.D., May Mo, M.S., Stephanie L. Roseti, A.P.N., M.S.N.,
More informationManagement of Severe Asthma Including Biologics and Bronchial Thermoplasty. Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC
Management of Severe Asthma Including Biologics and Bronchial Thermoplasty Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC Disclosures ALK speaker Monaghan Medical Corporation speaker Novartis speaker
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationOriginal. Koichi ANDO 1 2, Akihiko TANAKA 1, Tsukasa OHNISHI 1, Shin INOUE 2 and Hironori SAGARA 1
Showa Univ J Med Sci 30 2, 297 307, June 2018 Original Effectiveness of Therapeutic Monoclonal Antibodies for Asthma Control in Uncontrolled Eosinophilic Asthma A Meta-analysis of Randomized Controlled
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationTHE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
More informationRevisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications
doi: 10.1111/cea.12880 Clinical & Experimental Allergy, 47, 161 175 REVIEW 2017 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd Revisiting Type 2-high and Type 2-low airway
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationThe U.S. asthma population poses a significant burden
RESEARCH Clinical and Economic Burden of Blood Eosinophils in Patients With and Without Uncontrolled Asthma Julian Casciano, BS; Jerry Krishnan, MD, PhD; Zenobia Dotiwala, MS; Chenghui Li, PhD; and Shawn
More informationClinical profile of patients with adult-onset eosinophilic asthma
ORIGINAL ARTICLE ASTHMA Clinical profile of patients with adult-onset eosinophilic asthma Jantina C. de Groot 1, Huib Storm 2, Marijke Amelink 3, Selma B. de Nijs 3, Edwin Eichhorn 4, Bennie H. Reitsma
More informationCare pathways for the selection of a biologic in severe asthma
EDITORIAL ASTHMA Care pathways for the selection of a biologic in severe asthma Jean Bousquet 1,2,3, Guy Brusselle 4, Roland Buhl 5, William W. Busse 6, Alvaro A. Cruz 7,8, Ratko Djukanovic 9, Christian
More informationERJ Express. Published on December 12, 2013 as doi: /
ERJ Express. Published on December 12, 2013 as doi: 10.1183/09031936.00202013 International ERS/ATS Guidelines on Definition, Evaluation, and Treatment of Severe Asthma 2013 International ERS/ATS Guidelines
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More information